Status:
RECRUITING
Surgery Versus Biologics for Stricturing CD--a RCT
Lead Sponsor:
Zhu Weiming
Conditions:
Crohn Disease
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The management of stricturing Crohn's disease (CD) remains challenging. Although surgical resection may be the final way to solve it, the efficacy of biologics for symptomatic CD associated strictures...
Eligibility Criteria
Inclusion
- with intestinal obstructive symptoms;
- confirmed intestinal strictures;
- traditional drugs failed to induce remission;
- envidence of active bowel inflammation;
- inappropriate for EBD;
- acquirement of written informed consent of participant;
Exclusion
- unsuccessful medical treatment of intestinal obstruction;
- complete obstruction;
- contraindication for biologics;
- penetrating disease;
- short smaal bowel;
- suspicion of bowel tumor;
- no confirmed strictures;
- comitant severe disese of other system;
- obstructive symptoms under over 2 targets of biologics;
- successful treatment with traditional drugs;
- participate other clinical research.
Key Trial Info
Start Date :
June 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2030
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT05421455
Start Date
June 9 2022
End Date
June 1 2030
Last Update
July 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of General Surgery, Jinling hosptal,Medical School of Nanjing University
Nanjing, Jiangsu, China, 210002